JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

3.32 6.07

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.15

Max

3.32

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-15M 24M
Vorheriger Eröffnungskurs	-2.75
Vorheriger Schlusskurs	3.32

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Australian Flash PMI Bounce in April Conceals Deeper Worries

22. Apr. 2026, 23:33 UTC

Ergebnisse

SK Hynix Posts Record Quarterly Results Amid AI Boom

22. Apr. 2026, 22:40 UTC

Ergebnisse

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22. Apr. 2026, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22. Apr. 2026, 21:11 UTC

Ergebnisse

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22. Apr. 2026, 21:01 UTC

Ergebnisse

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22. Apr. 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22. Apr. 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22. Apr. 2026, 23:34 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22. Apr. 2026, 23:16 UTC

Ergebnisse

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22. Apr. 2026, 23:15 UTC

Ergebnisse

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22. Apr. 2026, 22:54 UTC

Ergebnisse

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22. Apr. 2026, 22:54 UTC

Ergebnisse

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22. Apr. 2026, 22:52 UTC

Ergebnisse

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22. Apr. 2026, 22:51 UTC

Ergebnisse

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22. Apr. 2026, 22:31 UTC

Ergebnisse

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22. Apr. 2026, 22:31 UTC

Ergebnisse

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22. Apr. 2026, 22:30 UTC

Ergebnisse

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22. Apr. 2026, 22:30 UTC

Ergebnisse

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22. Apr. 2026, 22:29 UTC

Ergebnisse

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22. Apr. 2026, 22:28 UTC

Ergebnisse

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22. Apr. 2026, 22:28 UTC

Ergebnisse

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22. Apr. 2026, 22:27 UTC

Ergebnisse

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22. Apr. 2026, 22:06 UTC

Market Talk

Ergebnisse

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22. Apr. 2026, 21:55 UTC

Akquisitionen, Fusionen, Übernahmen

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22. Apr. 2026, 21:47 UTC

Ergebnisse

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. Apr. 2026, 21:37 UTC

Ergebnisse

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22. Apr. 2026, 21:34 UTC

Ergebnisse

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22. Apr. 2026, 21:29 UTC

Ergebnisse

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. Apr. 2026, 21:20 UTC

Market Talk

Ergebnisse

Tesla Expands Manufacturing to Chips -- Market Talk

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.